Sense System with IBT Electrodes is an AI-enabled medical device from Infinite Biomedical Technologies, LLC that the U.S. FDA cleared through 510(k) K182112 on October 5, 2018. Its lead review panel is Neurology and its primary product code is GXY (Electrode, Cutaneous).
See also FDA-cleared AI neurology devices in 2018, all FDA AI clearances in 2018, top neurology AI devices.
Key facts
| Submission number | K182112 |
|---|---|
| Pathway | 510(k) |
| Date of final decision | |
| Company (FDA list) | Infinite Biomedical Technologies, LLC |
| Lead review panel | Neurology |
| Primary product code | GXY — Electrode, Cutaneous |
| Applicant (openFDA) | Infinite Biomedical Technologies, LLC |
| Applicant location | Baltimore, MD, US |
| Device class | Class 2 |
| Regulation number | 21 CFR 882.1320 |
| Decision code | SESE |
| Submission type | Traditional |
Source: FDA AI-Enabled Medical Devices list and openFDA.
What this means
A 510(k) is a premarket submission showing the device is substantially equivalent to a legally marketed predicate device. A cleared 510(k) means FDA agreed with that equivalence. Sense System with IBT Electrodes went through this pathway (K182112).
openFDA lists it as a Class 2 device under 21 CFR 882.1320. Class II devices are moderate risk and are subject to general and special controls.
Product code GXY covers 5 devices on the FDA AI list. By decision date, this device is #1 of 5 under that code. Infinite Biomedical Technologies, LLC has 1 AI-enabled device on the list, and the Neurology panel accounts for 73 in total.
Being on this list doesn't describe how well the device works clinically. Check the FDA record for its indications for use.
Similar devices (product code GXY)
- myosmart. (13E522); myosmart.cuff (757M20-2); connectgrip. (560X27-1); myosmart trial kit (642V64=T)Otto Bock Healthcare Products GmbH · Neurology
- Alpha Control Liner System (ACLS)Coapt · Neurology
- Myo PlusOtto Bock Healthcare Products GmbH · Neurology
- COMPLETE CONTROL System Gen2Coapt, LLC · Neurology